Archive for the ‘clinical cancer research’ Category
The retraction notices for “PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase” and “The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab” say the same thing: Read the rest of this entry »
Robert Getzenberg, formerly of the University of Pittsburgh and Johns Hopkins, has had two papers on prostate cancer biomarkers retracted, and two on colon cancer. The newly retracted paper is about a potential bladder cancer biomarker.
A group of cancer researchers formerly centered at Johns Hopkins have retracted two more studies. The previous two retracted papers — one of which was the focus of a lawsuit — were about prostate cancer, while the new retractions are of papers about colon cancer.
The International Journal of Cancer, a Wiley title, has retracted a pair of articles from a group at UT Southwestern Medical Center in Dallas, for image manipulation.
The first was titled “Aberrant methylation of Reprimo in human malignancies.” According to the retraction notice: Read the rest of this entry »